kisplyx 10 mg capsule
eisai pharma ag - lenvatinibum - capsule - lenvatinibum 10 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - behandlung von fortgeschrittenem nierenzellkarzinom (rcc) - synthetika
lenvima 4 mg capsule rigide
eisai pharma ag - lenvatinibum - capsule rigide - lenvatinibum 4 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - onkologikum - synthetika
lenvima 10 mg capsule rigide
eisai pharma ag - lenvatinibum - capsule rigide - lenvatinibum 10 mg ut lenvatinibi mesilas, calcii carbonas, mannitolum, cellulosum microcristallinum, hydroxypropylcellulosum, hydroxypropylcellulosum substitutum humile, talcum, kapselhülle: hypromellosum, e 171, e 172 (flavum), e 172 (rubrum), drucktinte: lacca, e 172 (nigrum), kalii hydroxidum, propylenglycolum, pro capsula. - onkologikum - synthetika
feiba
baxalta innovations gmbh - complesso protrombinico antiemofilico - complesso protrombinico antiemofilico
feiba nf 1000 e. injektionspräparat
takeda pharma ag - f. e. i. b. a. - injektionspräparat - preparazione cryodesiccata: proteinorum plasmatis soluzione umana 400-1200 mg corrisp. f. e. i. b. a. 1000 u., natrii citras dihydricus, natrii chloridum, per la preparazione. rilascio: acqua q.s. per una soluzione invece di 20 ml. - hemmkörperhämophilie con fattore viii o fattore ix-inibitore - emoderivati
feiba nf 2500 e. injektionspräparat
takeda pharma ag - f. e. i. b. a. - injektionspräparat - preparazione cryodesiccata: proteinorum plasmatis soluzione umana 1000-3000 mg corrisp. f. e. i. b. a. 2500 u., natrii citras dihydricus, natrii chloridum, per la preparazione. rilascio: acqua q.s. per una soluzione invece di 50 ml. - hemmkörperhämophilie con fattore viii o fattore ix-inibitore - emoderivati
roctavian
biomarin international limited - valoctocogene roxaparvovec - antiemorragici - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).
votrient
novartis europharm limited - pazopanib - carcinoma, cellule renali - agenti antineoplastici - carcinoma a cellule renali (rcc)votrient è indicato negli adulti per il trattamento di prima linea avanzate di carcinoma a cellule renali (rcc) e per i pazienti che hanno ricevuto una precedente terapia con citochine per malattia avanzata. il sarcoma dei tessuti molli (sts)votrient è indicato per il trattamento di pazienti adulti con selettiva sottotipi di avanzata sarcoma dei tessuti molli (sts) che hanno ricevuto una precedente chemioterapia per la malattia metastatica o che hanno progredito entro 12 mesi dopo (neo)adiuvante terapia. l'efficacia e la sicurezza sono stati stabiliti soltanto in alcuni sts istologico del tumore sottotipi.
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - neoplasie al seno - agenti antineoplastici - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.
kimmtrak
immunocore ireland limited - tebentafusp - uveal neoplasms - agenti antineoplastici - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.